{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:28:29Z","timestamp":1788406109017,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ajog.2022.11.1278","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T11:21:40Z","timestamp":1667992900000},"page":"320.e1-320.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials"],"prefix":"10.1016","volume":"228","author":[{"given":"Elizabeth A.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Lukes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Venturella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hunsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.11.1278_bib1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2022.11.1278_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/AOG.0b013e31820780e3","article-title":"Uterine leiomyomas: individualizing the approach to a heterogeneous condition","volume":"117","author":"Laughlin","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/GRF.0000000000000164","article-title":"Epidemiology of uterine fibroids: from menarche to menopause","volume":"59","author":"Wise","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib4","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1080\/03007995.2017.1372107","article-title":"Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey","volume":"33","author":"Soliman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ajog.2022.11.1278_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.AOG.0000165827.66541.dd","article-title":"Prospective data collection of a new procedure by a specialty society: the fibroid registry","volume":"106","author":"Myers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/IJWH.S133212","article-title":"Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis","volume":"9","author":"Fuldeore","year":"2017","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ajog.2022.11.1278_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2018.05.026","article-title":"Epidemiology of uterine myomas and clinical practice in Spain: an observational study","volume":"226","author":"Monle\u00f3n","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ajog.2022.11.1278_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpsychores.2014.12.016","article-title":"Beyond the physical: A qualitative assessment of the burden of symptomatic uterine fibroids on women\u2019s emotional and psychosocial health","volume":"78","author":"Ghant","year":"2015","journal-title":"J\u00a0Psychosom Res"},{"key":"10.1016\/j.ajog.2022.11.1278_bib10","doi-asserted-by":"crossref","first-page":"319.e1","DOI":"10.1016\/j.ajog.2013.07.017","article-title":"The impact of uterine leiomyomas: a national survey of affected women","volume":"209","author":"Borah","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197958","article-title":"Investigating the loss of work productivity due to symptomatic leiomyoma","volume":"13","author":"Hasselrot","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2022.11.1278_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/aogs.12292","article-title":"Heavy menstrual bleeding significantly affects quality of life","volume":"93","author":"Karlsson","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2022.11.1278_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.fertnstert.2019.10.028","article-title":"Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids","volume":"113","author":"Wallace","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.11.1278_bib14","doi-asserted-by":"crossref","first-page":"345.e1","DOI":"10.1016\/j.ajog.2019.09.052","article-title":"Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF fibroid registry","volume":"222","author":"Laughlin-Tommaso","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ajog.2020.05.044","article-title":"A\u00a0systematic review of the psychosocial impact of fibroids before and after treatment","volume":"223","author":"Go","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib16","first-page":"1","article-title":"Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT","volume":"26","author":"Daniels","year":"2022","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ajog.2022.11.1278_bib17","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"Miwa","year":"2011","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ajog.2022.11.1278_bib18","article-title":"Myfembree\u00ae (relugolix, estradiol, and norethindrone acetate) tablets, for oral use","year":"2022","journal-title":"Prescribing Information"},{"key":"10.1016\/j.ajog.2022.11.1278_bib19","unstructured":"European Medicines Agency. Ryeqo 40mg\/1mg\/0.5mg film-coated tablets. Summary of Product Characteristics (SmPC) 2022. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ryeqo. Accessed November 26, 2022."},{"key":"10.1016\/j.ajog.2022.11.1278_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.11.1278_bib21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000004787","article-title":"Relugolix combination therapy for uterine leiomyoma\u2013associated pain in the LIBERTY randomized trials","volume":"139","author":"Stewart","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib22","first-page":"290","article-title":"The UFS-QoL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib23","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jval.2022.06.005","article-title":"Development of the Bleeding and Pelvic Discomfort Scale for use in women with heavy menstrual bleeding associated with uterine fibroids","volume":"25","author":"Hudgens","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2022.11.1278_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00016346609158455","article-title":"Menstrual blood loss - a population study. Variation at different ages and attempts to define normality","volume":"45","author":"Hallberg","year":"1966","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2022.11.1278_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2022.11.1278_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s41687-019-0146-x","article-title":"Psychometric validation of the 1-month recall Uterine Fibroid Symptom and health-related quality of Life questionnaire (UFS-QoL)","volume":"3","author":"Coyne","year":"2019","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.ajog.2022.11.1278_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.11.12","article-title":"Interpreting patient-reported outcome results: US FDA guidance and emerging methods","volume":"11","author":"Mcleod","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ajog.2022.11.1278_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jval.2012.03.1387","article-title":"Validation of the UFS-QoL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research","volume":"15","author":"Coyne","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2022.11.1278_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.11.1278_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/AOG.0000000000003211","article-title":"Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Lukes","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.AOG.0000296526.71749.c9","article-title":"Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the fibroid registry","volume":"111","author":"Goodwin","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","article-title":"Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone","volume":"109","author":"Feng","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2022.11.1278_bib33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/02656736.2016.1212276","article-title":"Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China","volume":"32","author":"Liu","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ajog.2022.11.1278_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.11.1278_bib35","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jc.2016-3845","article-title":"Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women","volume":"102","author":"Ng","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2022.11.1278_bib36","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/humrep\/deab126.061","article-title":"O-136 once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks","volume":"36","author":"Lukes","year":"2021","journal-title":"Hum Reprod"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822021664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822021664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:41:46Z","timestamp":1757590906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822021664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0002937822021664"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.11.1278","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.11.1278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}